recombinant botulinum vaccine a/b
Vaccineexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2004 (NCT00098098)
Timeline
Indications
Studied for
Mechanism of action
- Clostridium botulinum AImmunity, active
Clostridium botulinum A immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- recombinant botulinum vaccine a/b
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06112834 | Phase 2 | Jun 30, 2024 | California Department of Public Health |
| NCT01940315 | Phase 3 | Oct 1, 2020 | DynPort Vaccine Company LLC |
| NCT03676634 | Phase 2 | Feb 28, 2019 | California Department of Public Health |
| NCT01701999 | Phase 2 | Feb 1, 2013 | California Department of Public Health |
| NCT00764634 | Phase 2 | Sep 1, 2008 | DynPort Vaccine Company LLC |
| NCT00098098 | Phase 1 | Aug 1, 2004 | DynPort Vaccine Company LLC, University of Kentucky |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| California Department of Public Health | Government | 3 | 3 | 1 | 2013 |
| DynPort Vaccine Company LLC | For profit | 3 | 3 | 3 | 2004 |
| University of Kentucky | Academic/Hospital | 1 | 0 | 1 | 2004 |
3 organizations
Page 1 / 1